Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma : results from the phase II nonrandomized KEYNOTE-059 study
dc.contributor.author | Bang, Y.J. | |
dc.contributor.author | Kang, Y.K. | |
dc.contributor.author | Catenacci, D.V. | |
dc.contributor.author | Muro, K. | |
dc.contributor.author | Fuchs, C.S. | |
dc.contributor.author | Geva, R. | |
dc.contributor.author | Hara, H. | |
dc.contributor.author | Golan, T. | |
dc.contributor.author | Garrido S., Marcelo | |
dc.contributor.author | Jalal, S.I. | |
dc.contributor.author | Borg, C. | |
dc.contributor.author | Doi, T. | |
dc.contributor.author | Yoon, H.H. | |
dc.contributor.author | Savage, M.J. | |
dc.contributor.author | Wang, J. | |
dc.contributor.author | Dalal, R.P. | |
dc.contributor.author | Shah, S. | |
dc.contributor.author | Wainberg, Z.A. | |
dc.contributor.author | Chung, H.C. | |
dc.date.accessioned | 2021-05-31T03:47:24Z | |
dc.date.available | 2021-05-31T03:47:24Z | |
dc.date.issued | 2019 | |
dc.format.extent | 10 páginas | |
dc.fuente.origen | Converis | |
dc.identifier.doi | 10.1007/s10120-018-00909-5 | |
dc.identifier.eissn | 1436-3305 | |
dc.identifier.issn | 1436-3291 | |
dc.identifier.uri | https://doi.org/10.1007/s10120-018-00909-5 | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/60298 | |
dc.identifier.wosid | WOS:000471727400019 | |
dc.issue.numero | No. 4 | |
dc.language.iso | en | |
dc.nota.acceso | Contenido completo | |
dc.pagina.final | 837 | |
dc.pagina.inicio | 828 | |
dc.revista | Gastric Cancer | es_ES |
dc.rights | acceso abierto | |
dc.subject.ddc | 610 | |
dc.subject.dewey | Medicina y salud | es_ES |
dc.subject.ods | 03 Good health and well-being | |
dc.subject.odspa | 03 Salud y bienestar | |
dc.subject.other | Adenocarcinoma - Tratamiento farmacológico | es_ES |
dc.subject.other | Neoplasias esofágicas | es_ES |
dc.title | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma : results from the phase II nonrandomized KEYNOTE-059 study | es_ES |
dc.type | artículo | |
dc.volumen | Vol. 22 | |
sipa.codpersvinculados | 7260 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal.pdf
- Size:
- 641.16 KB
- Format:
- Adobe Portable Document Format
- Description: